Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 4000
- Registration Number
- NCT06705608
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Children's National Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT06358638
- Locations
- 🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
ADAs to Alemtuzumab
- Conditions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 15
- Registration Number
- NCT06310343
- Locations
- 🇬🇧
Barts Health NHS Trust, London, Second Floor Neurophys Dept, United Kingdom
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06084780
- Locations
- 🇺🇸
Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 60
- Registration Number
- NCT05501756
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 50
- Registration Number
- NCT05463133
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05384756
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 90
- Registration Number
- NCT05357482
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 1
- Registration Number
- NCT04971005
- Locations
- 🇩🇪
Universitätsklinikum Mannheim, Mannheim, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT04339777
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.